Extended Abstract
Volume 4:2, 2018

Journal of Oncology Translational Research

Open Access

Disaccharide Mimetics as Drugs Against Cancer and Epitopes for Anti-Cancer Vaccine Candidates

Pierre Vogel* and Loay Awad

Swiss Institute of Technology in Lausanne (EPFL), Switzerland. E-mail: Pierre.vogel@epfl.ch

Abstract

Cancer could be a cluster of diseases involving abnormal cell growth with the potential to invade or unfold to different elements of the body. This distinction with benign tumors, that don't unfold. Potential signs and symptoms embody a lump, abnormal hemorrhage, prolonged cough, unexplained weight loss, and an amendment in internal organ movements. Over two hundred forms of cancers have an effect on humans. Usually cancer leads to uncommon, uncontrollable division and different impairment that may be fatal. Some forms of cancer cause speedy cell growth, whereas others cause cells to grow and divide at a slower rate. Certain cancers end in visible growths referred to as tumors, whereas others, like leukemia, do not. Most of the body's cells have specific functions and glued lifespans. Whereas it's going to sound sort of a dangerous factor, death is an element of a natural and helpful development referred to as cascade-mediated cell death. A cell receives directions to die so the body will replace it with a more modern cell that functions higher. Cancerous cells lack the elements that instruct them to prevent dividing and to die.

As a result, they build up within the body, victimization chemical element and nutrients that may typically nourish different cells. Cancerous cells will kind tumors, impair the system and cause different changes that forestall the body from functioning frequently.
Other causes of cancer don't seem to be preventable. Currently, the foremost important unpreventable risk issue is age. Genetic factors will contribute to the event of cancer. Changes within the genes will cause faulty directions, and cancer may result. Genes additionally influence the cells' production of proteins, and proteins carry several of the directions for cellular growth and division. Some genes amendment proteins that may typically repair broken cells. This may cause cancer. If a parent has these genes, they'll depart this world the altered directions to their offspring. Chemotherapy aims to kill cancerous cells with medications that concentrate on quickly dividing cells. The medicine may facilitate shrink tumors; however the aspect effects will be severe. Hormone medical care involves taking medications that amendment however bound hormones work or interfere with the body's ability to supply them. Once hormones play a big role, like prostate and breast cancers, this is often a standard approach. Immunotherapy uses medications and different treatments to spice up the system and encourage it to fight cancerous cells. Samples of these treatments stop inhibitors and adoptive cell transfer. Precision drugs, or customized drugs, are a newer, developing approach. It involves victimization genetic testing to see the simplest treatments for a person's explicit presentation of cancer. Radiation therapy uses high-dose radiation to kill cancerous cells. Stem cell transplant will be particularly helpful for individuals with related cancers, like cancer of the blood. It involves removing cells, like red or white blood cells, that therapy or radiation has destroyed. Research laboratory technicians then strengthen the cells and place them into the body.

The outer space of a typical aerodigestive animal tissue surface consists of secreted gel-forming mucins, and is a degree of interface with air, food, enzymes, acid pH, salt, bacterium and viruses. The secreted glycoprotein layer may additionally contact the cell surface through interactions with membrane-associated mucins or different cell-surface molecules. Complex glycoprotein gels are shown to capture and hold biologically active molecules that may operate as indicators of molecular or physical breach of the glycoprotein layer and, following their unleash, may incite inflammatory, repair or healing processes. Cell-surface-associated mucins are guaranteed to cells by Associate in nursing integral trans membrane domain and have comparatively short protoplasm tails that keep company with cytoskeletal components, cytosolic device proteins and/or participate in signal transduction. Mucins may function cell-surface receptors and sensors, and conduct signals in response to external stimuli that cause coordinated cellular responses that embody proliferation, differentiation, cascade-mediated cell death or secretion of specialized cellular merchandise

Cancer-associated mucin glycoprotein MUC1 is characterized by the presence of altered carbohydrates such as Tn (□-N-acetylgalactosamine), sTn (sialyl-1-6-Tn) and the Thomsen-Friedenreich (TF: □-D-Galp-1-3□□-D-GalNAc*p*) antigen (tumor associated carbohydrate antigens: TACAs) that are conjugated to proteins *via* O-□-galactosylation of serine or/and threonine. Patients immunized with synthetic TF conjugated with KLH (keyhole limpet hemocyanin) + QS21 adjuvant can generate IgM and IgG antibodies.[1] Because the disaccharide TF is hydrolyzed rapidly in the body, strong immune response requires longer lived disaccharides. Fluororinated TACAs have been proposed which elicit IgG antibodies found to cross-react with native TF epitopes. We have found that the C-linked disaccharide analogue (constructed applying Danishesky's method for the conjugation with KLH [4]) + QS21 adjuvant induces a strong immune response in mice. Interestingly, much weaker immune response was observed with a stereoisomeric antigen constructed with the □-C-galactoside analogue of TF

disaccharide(□-D-Galp-1-CH_2-3-□-D-GalNAc-O-Ser).[5]
Several strategies and methods have been developed for the synthesis of C-linked disaccharides including disaccharide mimetics incorporating iminosugars C-linked to sugars and sugar mimetics such as conduritols and cyclitols. The latter work was motivated by the search for specific glycosidase and glycosyltransferase inhibitors that are potential drugs against cancers and other diseases.



Biography

Pierre Vogel is Hon. Prof of the Swiss Institute of Technology in Lausanne (EPFL). He obtained a master degree from that school in 1966, and a Ph.D. degree from the Univ. of Lausanne in 1969 (Prof. H. Prinzbach). He then stayed two years at Yale University (post-doct.; Prof. M. Saunders, J. A. Berson) and joined Syntex in Mexico City (Prof. P. Crabbé). He returned to the Univ. of Lausanne where he became full-prof. of organic chemistry in 1977. In 2001 he joined the EPFL and acted as chairman of the doctoral program in chemistry and chemical engineering of this school until his retirement in 2010. He collaborates with European colleagues on the search of anti-cancer drugs. He is the head of a small laboratory doing medicinal chemistry, hosted by the EPFL. Together with Prof. Kendall N. Houk (UCLA) he has published recently (Wiley-VCH) a textbook: Organic Chemistry: Theory, Reactivity and Mechanisms in Modern Synthesis.